NorthWest Biotherapeutics Inc (NWBO)

[hope4patients]

Let's play "who wrote this":

"In the US and EU, the addressable glioma market alone would make up for over 60,000 treatments/yr. at $70K/tx (conservative), or $4.2B in sales. Over a $10B market cap. And it would happen quickly, within 2-3 years from approval.

DCVax-Direct, once it comes further along in trials, will likely follow suit, as it is such a novel conceptualized therapy with good patent protection and really nothing like it by comparison, and clearly showing early signs of strong efficacy.

But regarding DCVax-L, I don't think you'll ever again see so much foreshadowing of a treatment's effectiveness before the release of clinical results in an ongoing, double-blind Ph III trial like we have here. A $300mm market cap (or even $1B, for that matter) looks like a bargain."